BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Foy KC, Liu Z, Phillips G, Miller M, Kaumaya PT. Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo. J Biol Chem 2011;286:13626-37. [PMID: 21325276 DOI: 10.1074/jbc.M110.216820] [Cited by in Crossref: 38] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Foy KC, Miller MJ, Moldovan N, Bozanovic T, Carson WE 3rd, Kaumaya PT. Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer. Oncoimmunology 2012;1:1004-16. [PMID: 23170249 DOI: 10.4161/onci.21057] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
2 Foy KC, Wygle RM, Miller MJ, Overholser JP, Bekaii-Saab T, Kaumaya PT. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo. J Immunol. 2013;191:217-227. [PMID: 23698748 DOI: 10.4049/jimmunol.1300231] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
3 Kaumaya PT. B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine. Future Oncol 2020;16:1767-91. [PMID: 32564612 DOI: 10.2217/fon-2020-0224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Overholser J, Ambegaokar KH, Eze SM, Sanabria-Figueroa E, Nahta R, Bekaii-Saab T, Kaumaya PT. Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). Vaccines (Basel) 2015;3:519-43. [PMID: 26350593 DOI: 10.3390/vaccines3030519] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
5 Krupinski J, Abudawood M, Matou-Nasri S, Al-Baradie R, Petcu EB, Justicia C, Planas A, Liu D, Rovira N, Grau-Slevin M, Secades J, Slevin M. Citicoline induces angiogenesis improving survival of vascular/human brain microvessel endothelial cells through pathways involving ERK1/2 and insulin receptor substrate-1. Vasc Cell 2012;4:20. [PMID: 23227823 DOI: 10.1186/2045-824X-4-20] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
6 Chen Y, Luo W, Song H, Yin B, Tang J, Chen Y, Ng MH, Yeo AE, Zhang J, Xia N. Mimotope ELISA for detection of broad spectrum antibody against avian H5N1 influenza virus. PLoS One 2011;6:e24144. [PMID: 21912666 DOI: 10.1371/journal.pone.0024144] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
7 Fan X, Jin WY, Lu J, Wang J, Wang YT. Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation. Nat Neurosci 2014;17:471-80. [PMID: 24464042 DOI: 10.1038/nn.3637] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 8.5] [Reference Citation Analysis]
8 Koskimaki JE, Lee E, Chen W, Rivera CG, Rosca EV, Pandey NB, Popel AS. Synergy between a collagen IV mimetic peptide and a somatotropin-domain derived peptide as angiogenesis and lymphangiogenesis inhibitors. Angiogenesis 2013;16:159-70. [PMID: 23053781 DOI: 10.1007/s10456-012-9308-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
9 Gompels LL, Malik NM, Madden L, Jin P, Feldmann M, Shepard HM, Paleolog EM. Human epidermal growth factor receptor bispecific ligand trap RB200: abrogation of collagen-induced arthritis in combination with tumour necrosis factor blockade. Arthritis Res Ther 2011;13:R161. [PMID: 21982514 DOI: 10.1186/ar3480] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
10 Rau KM, Huang CC, Chiu TJ, Chen YY, Lu CC, Liu CT, Pei SN, Wei YC. Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers. Exp Ther Med 2012;4:231-6. [PMID: 23139713 DOI: 10.3892/etm.2012.594] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
11 Tino AB, Chitcholtan K, Sykes PH, Garrill A. Resveratrol and acetyl-resveratrol modulate activity of VEGF and IL-8 in ovarian cancer cell aggregates via attenuation of the NF-κB protein. J Ovarian Res 2016;9:84. [PMID: 27906095 DOI: 10.1186/s13048-016-0293-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
12 Kaumaya PT. A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy. Hum Vaccin Immunother 2015;11:1368-86. [PMID: 25874884 DOI: 10.1080/21645515.2015.1026495] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
13 Kaumaya PT, Foy KC. Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Future Oncol. 2012;8:961-987. [PMID: 22894670 DOI: 10.2217/fon.12.95] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
14 Laengsri V, Nantasenamat C, Schaduangrat N, Nuchnoi P, Prachayasittikul V, Shoombuatong W. TargetAntiAngio: A Sequence-Based Tool for the Prediction and Analysis of Anti-Angiogenic Peptides. Int J Mol Sci 2019;20:E2950. [PMID: 31212918 DOI: 10.3390/ijms20122950] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
15 Doti N, Mardirossian M, Sandomenico A, Ruvo M, Caporale A. Recent Applications of Retro-Inverso Peptides. Int J Mol Sci 2021;22:8677. [PMID: 34445382 DOI: 10.3390/ijms22168677] [Reference Citation Analysis]
16 Medeiros Da Cunha CM, Perugini V, Bernegger P, Centola M, Barbero A, Guildford AL, Santin M, Banfi A, Martin I, Marsano A. Vascular Endothelial Growth Factor Sequestration Enhances In Vivo Cartilage Formation. Int J Mol Sci 2017;18:E2478. [PMID: 29160845 DOI: 10.3390/ijms18112478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
17 Miller MJ, Foy KC, Overholser JP, Nahta R, Kaumaya PT. HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells. Oncoimmunology 2014;3:e956012. [PMID: 25941588 DOI: 10.4161/21624011.2014.956012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
18 Foy KC, Miller MJ, Overholser J, Donnelly SM, Nahta R, Kaumaya PT. IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides. Oncoimmunology 2014;3:e956005. [PMID: 25941587 DOI: 10.4161/21624011.2014.956005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
19 Guo L, Overholser J, Good AJ, Ede NJ, Kaumaya PTP. Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys). Front Oncol 2022;12:826566. [DOI: 10.3389/fonc.2022.826566] [Reference Citation Analysis]
20 González PL, Carvajal C, Cuenca J, Alcayaga-Miranda F, Figueroa FE, Bartolucci J, Salazar-Aravena L, Khoury M. Chorion Mesenchymal Stem Cells Show Superior Differentiation, Immunosuppressive, and Angiogenic Potentials in Comparison With Haploidentical Maternal Placental Cells. Stem Cells Transl Med 2015;4:1109-21. [PMID: 26273064 DOI: 10.5966/sctm.2015-0022] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
21 Nahta R. Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance. Curr Med Chem 2012;19:1065-75. [PMID: 22229414 DOI: 10.2174/092986712799320691] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 4.5] [Reference Citation Analysis]